A PYMNTS Company

EU: At $34.10 billion, Perrigo rejects Mylan again

By  |  April 29, 2015

Mylan boosted its cash-and-stock offer to buy Perrigoto $34.10 billion, a bid that was swiftly rejected.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Mylan’s pursuit of Perrigo, a major producer of over-the-counter drugs, is widely seen as an attempt to fend off a $40 billion offer from Teva Pharmaceutical Industries the world’s biggest maker of generic drugs.

    Mylan’s latest offer comprised $75 in cash and 2.3 of its shares for each Perrigo share, up from its previous offer of $60 in cash and 2.2 of its shares.

    Perrigo’s rejection further intensifies a three-way battle to gain abigger share of the generic drugs market as more leading drugs lose patent protection.

    “Today’s announcement from Mylan continues to propose a price lower than the previously rejected proposal,” Perrigo said.

     

    Full Content: The New York Times

     

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.